Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Calligaro

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pediatric Pulmonology|October 15, 2025
Cystic Fibrosis Care in South Africa: Facing the Challenge of Diversity and InequalityMarco Zampoli, Cathy Baird, Brenda Morrow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?Grant Theron, Rouxjeane Venter, Greg Calligaro, et al.
Journal of Clinical Microbiology|January 7, 2018
False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical OutcomesGrant Theron, Rouxjeane Venter, Liezel Smith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2015
Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case SeriesIlan S Schwartz, Nelesh P Govender, Craig Corcoran, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 5, 2025
Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce costMarco Zampoli, Janine Verstraete, Cathy Baird, et al.
BMC Pulmonary Medicine|April 9, 2014
Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-γ for the evaluation of pleural tuberculosis: a prospective cohort studyRichard Meldau, Jonny Peter, Grant Theron, et al.
The European Respiratory Journal|November 15, 2011
Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?Grant Theron, Anil Pooran, Jonny Peter, et al.
Scientific Reports|July 12, 2014
Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartmentsGrant Theron, Jonny Peter, Greg Calligaro, et al.
Nature Medicine|July 1, 2020
Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosisGrant Theron, Jason Limberis, Rouxjeane Venter, et al.
Lancet (London, England)|March 14, 2016
Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trialJonny G Peter, Lynn S Zijenah, Duncan Chanda, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pediatric Pulmonology|October 15, 2025
Cystic Fibrosis Care in South Africa: Facing the Challenge of Diversity and InequalityMarco Zampoli, Cathy Baird, Brenda Morrow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?Grant Theron, Rouxjeane Venter, Greg Calligaro, et al.
Journal of Clinical Microbiology|January 7, 2018
False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical OutcomesGrant Theron, Rouxjeane Venter, Liezel Smith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2015
Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case SeriesIlan S Schwartz, Nelesh P Govender, Craig Corcoran, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 5, 2025
Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce costMarco Zampoli, Janine Verstraete, Cathy Baird, et al.
BMC Pulmonary Medicine|April 9, 2014
Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-γ for the evaluation of pleural tuberculosis: a prospective cohort studyRichard Meldau, Jonny Peter, Grant Theron, et al.
The European Respiratory Journal|November 15, 2011
Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?Grant Theron, Anil Pooran, Jonny Peter, et al.
Scientific Reports|July 12, 2014
Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartmentsGrant Theron, Jonny Peter, Greg Calligaro, et al.
Nature Medicine|July 1, 2020
Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosisGrant Theron, Jason Limberis, Rouxjeane Venter, et al.
Lancet (London, England)|March 14, 2016
Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trialJonny G Peter, Lynn S Zijenah, Duncan Chanda, et al.
Pageof 2